Non Small Cell Lung Cancer Stage III Clinical Trial
Official title:
High Intensity Functional Image Guided Vmat Lung Evasion
This study is being performed to assess the feasibility of adapting radiotherapy plans based on functional lung information and increasing the dose to the primary tumour. This is a single arm interventional pilot study involving 20 patients. Aims Primary: to assess the feasibility of using ventilation and perfusion positron emission computed tomography (V/Q PET/CT) scans to adapt radiotherapy plans using Volumetric Modulated Arc Therapy (VMAT) to avoid regions of functional lung and deliver a higher dose to the primary tumour Secondary: to assess the incidence of acute and late radiotherapy toxicities, to quantify regional ventilation loss and regional perfusion loss on post treatment V/Q PET/CT, to assess associations of V/Q PET/CT with other functional lung imaging techniques, to assess overall survival, progression free survival and quality of life outcomes. Participants: 20 patients stage IIIa-c non-small cell lung cancer for curative intent radiotherapy. Methods: All patients will receive functional lung adapted 60 Gray (Gy) in 30 fractions to the primary and nodal planning target volume with a simultaneous integrated boost to the primary tumour to a total dose 69Gy in 30 fractions. Expected outcomes: That functionally adapted lung radiotherapy using V/Q PET/CT imaging and VMAT planning is technically feasible.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT02247713 -
An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries
|
N/A | |
| Recruiting |
NCT04711330 -
Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy
|
||
| Not yet recruiting |
NCT04465968 -
Efficacy and Safety of CRT, Durvalumab and Surgery for SST
|
Phase 3 | |
| Completed |
NCT03845270 -
Her2-positive Lung Cancer Treated With Dedicated Drug
|
Phase 2 | |
| Active, not recruiting |
NCT04392505 -
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
|
Phase 2 | |
| Completed |
NCT04577638 -
Accelerated Radio-Immunotherapy for Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05382052 -
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
|
||
| Terminated |
NCT04289259 -
Tumor Mutational Burden in Lung Cancer Patients
|
||
| Recruiting |
NCT04672759 -
A Real-world Study of Durvalumab for Lung Cancer in China
|
||
| Recruiting |
NCT02622581 -
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
|
||
| Completed |
NCT03055715 -
Prognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLC
|